

Applicant : Gary L. Nelsestuen  
Serial No. : 09/302,239  
Filed : April 29, 1999  
Page : 2 of 6

Attorney's Docket No.: 09531-005001 / 97141

In the claims:

Please amend the claims as follows:

1. (Currently amended) A ~~Factor VII or~~ Factor VIIa polypeptide comprising a modified GLA domain that enhances membrane binding affinity and activity of said polypeptide relative to a corresponding native ~~Factor VII or~~ Factor VIIa polypeptide, said modified GLA domain comprising ~~at least one~~ an amino acid substitution at residue 10 or residue 28 of SEQ ID NO:3 or SEQ ID NO:4.

2. (Cancelled)

2. (Previously amended) The polypeptide of claim 1, wherein a glutamine, a glutamic acid, an aspartic acid, or an asparagine residue is substituted at residue 10 of SEQ ID NO:3 or SEQ ID NO:4.

3. (Previously amended) The polypeptide of claim 2, wherein a glutamine residue is substituted at residue 10 of SEQ ID NO:3 or SEQ ID NO:4.

4. (Previously amended) The polypeptide of claim 1, wherein a glutamic acid or a phenylalanine residue is substituted at residue 28 of SEQ ID NO:3 or SEQ ID NO:4.

6. (Cancelled)

11. (Previously amended) The polypeptide of claim 1, wherein said modified GLA domain further comprises an amino acid substitution at residue 32 of SEQ ID NO:3 or SEQ ID NO:4.

12. (Previously amended) The polypeptide of claim 11, wherein a glutamic acid or an aspartic acid is substituted at residue 32 of SEQ ID NO:3 or SEQ ID NO:4.

Applicant : Gary L. Nelsestuen  
Serial No. : 09/302,239  
Filed : April 29, 1999  
Page : 3 of 6

Attorney's Docket No.: 09531-005001 / 97141

4  
9. (Previously amended) The polypeptide of claim 2, wherein said modified GLA domain further comprises a substitution of a glutamic acid or an aspartic acid at residue 32 of SEQ ID NO:3 or SEQ ID NO:4.

10  
10. (Previously amended) The polypeptide of claim 5, wherein said modified GLA domain further comprises a substitution of a glutamic acid or an aspartic acid at residue 32 of SEQ ID NO:3 or SEQ ID NO:4.

6  
11. (Previously amended) The polypeptide of claim 3, wherein said modified GLA domain further comprises a substitution of a glutamic acid or a phenylalanine at residue 28 of SEQ ID NO:3 or SEQ ID NO:4.

7  
12. (Previously amended) The polypeptide of claim 11, wherein said modified GLA domain comprises a glutamic acid or an aspartic acid residue at amino acid 32 of SEQ ID NO:3 or SEQ ID NO:4.

5  
13. (Previously amended) The polypeptide of claim 9, wherein said modified GLA domain comprises a glutamine residue at amino acid 10 and a glutamic acid residue at amino acid 32 of SEQ ID NO:3 or SEQ ID NO:4.

8  
14. (Previously amended) The polypeptide of claim 11, wherein said modified GLA domain comprises a substitution of a glutamine at residue 10 and a phenylalanine at residue 28 of SEQ ID NO:3 or SEQ ID NO:4.

15. (Cancelled)

13  
16. (Previously amended) The polypeptide of claim 1, wherein said polypeptide comprises active-site modified Factor VIIa.

Applicant : Gary L. Nelsestuen  
Serial No. : 09/302,239  
Filed : April 29, 1999  
Page : 4 of 6

Attorney's Docket No.: 09531-005001 / 97141

14 <sup>14</sup>  
17. (Currently amended) A ~~Factor VII~~ or Factor VIIa polypeptide comprising a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native ~~Factor VII~~ or Factor VIIa polypeptide, said modified GLA domain comprising an aspartic acid residue at amino acid 32 of SEQ ID NO:3 or SEQ ID NO:4.

18-22. (Cancelled)

*Ex 1*  
*com*  
*hide*  
15 <sup>15</sup>  
23. (Currently amended) A ~~Factor VII~~ or Factor VIIa polypeptide comprising a modified GLA domain that enhances membrane binding affinity of said polypeptide relative to a corresponding native ~~Factor VII~~ or Factor VIIa polypeptide, said modified GLA domain consisting essentially of the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:4 with two or more amino acid substitutions at two or more of the residues selected from the group consisting of residues 10, 11, 28, and 32 of ~~SEQ ID NO:3 or SEQ ID NO:4~~.

16 <sup>15</sup>  
24. (Previously added) The polypeptide of claim <sup>15</sup>23, wherein a glutamine, a glutamic acid, an aspartic acid, or an asparagine residue is substituted at residue 10 of SEQ ID NO:3 or SEQ ID NO:4.

17 <sup>15</sup>  
25. (Previously added) The polypeptide of claim <sup>15</sup>23, wherein a glutamine residue is substituted at residue 10 of SEQ ID NO:3 or SEQ ID NO:4.

18 <sup>15</sup>  
26. (Previously added) The polypeptide of claim <sup>15</sup>23, wherein a glutamic acid or an aspartic acid is substituted at residue 32 of SEQ ID NO:3 or SEQ ID NO:4.

19 <sup>15</sup>  
27. (Previously added) The polypeptide of claim <sup>15</sup>23, wherein a glutamine, a glutamic acid, an aspartic acid, or an asparagine residue is substituted at residue 10 of SEQ ID NO:3 or SEQ ID NO:4 and a glutamic acid or an aspartic acid is substituted at residue 32 of SEQ ID NO:3 or SEQ ID NO:4.